Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

NASDAQ:KNSA 4:00:00 PM EDT

17.10

+0.18 (+1.09%)

7:08:18 PM EDT: $18.10 +1.01 (+5.88%)

Market Cap (Intraday)	1.21B
Current PE	85.71
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$76.97 Million
Adjusted EPS	-$0.14

See more estimates

10-Day MA	$17.32
50-Day MA	$19.36
200-Day MA	$17.67

See more pivots

Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A Stock, NASDAQ:KNSA

100 Hayden Avenue, 2 Church Street, Lexington, Massachusetts 02421

Bermuda

Phone: +1.781.431.9100

Number of Employees: 297

http://www.kiniksa.com

Description

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.